Comparative Effectiveness of 100 mg/kg Levetiracetam Injection in Two Different Epilepsy Models: Temporal Lobe Epilepsy and Genetic Absence Epilepsy

Levetiracetam (LEV), approved as a single agent in the early 2000s, is a widely used broad-spectrum second-generation anti-seizure drug (ASD) in the treatment of focal-onset seizures and focal to bilateral tonic-clonic seizures [previously known as partial seizures and partial seizures with secondary generalization, such as temporal lobe epilepsy (TLE)]. 1 LEV is also prescribed for children with epilepsy characterized primarily by typical absence seizures.It is approved for adjunctive therapy for the treatment of myoclonic seizures in adults and juvenile myoclonic epilepsy in adolescents over the age of 12 years, and primary generalized tonic-clonic seizures in adults and children over five years old with idiopathic generalized epilepsy. [2][3]3][4] In a randomized, placebo-controlled trial of LEV in children and adolescents with newly diagnosed childhood or juvenile absence epilepsy, 23.7% of patients responded to LEV monotherapy. 5In a shortterm randomized, placebo-controlled study to determine whether LEV is efficacious in controlling typical absence seizures in patients with newly diagnosed childhood or juvenile absence epilepsy, LEV treatment caused an aggravation of childhood absence epilepsy patients and increased the daily number of absence seizures. 6The progressive decrease of LEV dose was followed by a corresponding reduction in absence seizures in these patients.